Paris, 11 October 2017: A biotechnology company listed on the Euronext Growth market of Euronext Paris, Biophytis specialises in the development of drug candidates to treat diseases connected to ageing. This capital increase will allow it to continue its clinical development programmes in the field of Sarcopenia and Age-related Macular Degeneration (AMD).
This transaction, in the form of a private placement, consists of the issuing of 1,989,000 new ordinary shares at a price of €5.25 per share for a total of €10,442,500, representing 20% of the company’s capital.
It provides Biophytis with the means and flexibility to finance the programme of development of its pipeline in diseases related to ageing. This will allow the company, in particular, to finance the launching of the SARA-INT interventional, multicentre and international study and the MACA-PK multicentre and international clinical study.
Jean-Emmanuel Vernay and Vincent Dechin of Invest Corporate Finance said: “We are very proud to have been able to assist Biophytis in this further capital increase. This operation constitutes a major stage of their development and confirms the support of first-class European investors who thereby express their confidence in the potential of the company”.
Pascal Hadjedj of Invest Securities added: “This operation proves the lasting relationship of trust which we have with Biophytis and illustrates the synergies permitted by the integration of our various skills within Allinvest for the benefit of the growth of our customers”.
Executives involved in the transaction
Global coordinator of the operation: Invest Corporate Finance (Jean-Emmanuel Vernay, Vincent Déchin and Maxime Bazin)
Sole placement agent in Europe: Invest Securities (Pascal Hadjedj)
Sole placement agent in the United States: HC Wainwright
Biophytis press release